Trial Profile

Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Pembrolizumab (Primary)
Indications Extranodal NK-T-cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Therapeutic Use

Most Recent Events

06 Oct 2023 Planned initiation date changed from 15 Mar 2022 to 1 Mar 2020.
06 Oct 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
07 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com